Charles River Laboratories International, Inc. $CRL Shares Purchased by New York Life Investment Management LLC

New York Life Investment Management LLC lifted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 371.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 61,506 shares of the medical research company’s stock after purchasing an additional 48,455 shares during the period. New York Life Investment Management LLC’s holdings in Charles River Laboratories International were worth $18,145,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Handelsbanken Fonder AB grew its holdings in Charles River Laboratories International by 36.9% during the 2nd quarter. Handelsbanken Fonder AB now owns 19,306 shares of the medical research company’s stock worth $4,378,000 after acquiring an additional 5,200 shares during the last quarter. Avidity Partners Management LP acquired a new position in Charles River Laboratories International in the 1st quarter valued at approximately $1,670,000. Quantitative Investment Management LLC bought a new position in shares of Charles River Laboratories International during the second quarter valued at $1,360,000. Madison Asset Management LLC bought a new position in shares of Charles River Laboratories International during the second quarter valued at $3,805,000. Finally, TD Waterhouse Canada Inc. raised its stake in shares of Charles River Laboratories International by 81,468.9% during the third quarter. TD Waterhouse Canada Inc. now owns 36,706 shares of the medical research company’s stock valued at $10,829,000 after acquiring an additional 36,661 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $342.81 on Thursday. The company has a market capitalization of $16.43 billion, a PE ratio of 376.71, a P/E/G ratio of 3.13 and a beta of 1.36. The company has a 50 day simple moving average of $309.32 and a two-hundred day simple moving average of $227.05. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.12 and a current ratio of 1.41. Charles River Laboratories International, Inc. has a fifty-two week low of $146.20 and a fifty-two week high of $379.63.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, November 4th. The medical research company reported $3.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.97 by $0.12. The firm had revenue of $982.73 million during the quarter, compared to analyst estimates of $960.36 million. Charles River Laboratories International had a net margin of 1.01% and a return on equity of 16.95%. The company’s revenue was down 2.2% compared to the same quarter last year. During the same quarter last year, the business earned $2.43 EPS. Research analysts anticipate that Charles River Laboratories International, Inc. will post 11.45 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. TD Cowen reiterated a “buy” rating on shares of Charles River Laboratories International in a report on Wednesday. Zacks Research downgraded Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a report on Monday, November 2nd. Argus set a $330.00 target price on Charles River Laboratories International in a research report on Thursday, September 17th. Piper Sandler set a $300.00 target price on Charles River Laboratories International in a research report on Monday, August 10th. Finally, Evercore set a $330.00 target price on Charles River Laboratories International in a report on Friday, September 25th. Thirteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $308.17.

Insider Transactions at Charles River Laboratories International

In related news, EVP Shannon M. Parisotto sold 2,156 shares of Charles River Laboratories International stock in a transaction on Wednesday, October 21st. The shares were sold at an average price of $344.41, for a total transaction of $742,547.96. Following the completion of the transaction, the executive vice president owned 4,807 shares of the company’s stock, valued at $1,655,578.87. This trade represents a 30.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director James Foster sold 24,042 shares of the business’s stock in a transaction on Thursday, October 22nd. The shares were sold at an average price of $350.00, for a total transaction of $8,414,700.00. Following the completion of the transaction, the director owned 31,596 shares in the company, valued at approximately $11,058,600. The trade was a 43.21% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 63,352 shares of company stock worth $20,291,281 over the last three months. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.